MFW
NVCR icon

Meristem Family Wealth’s NovoCure NVCR Stock Holding History

Meristem Family Wealth’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,886
Closed -$249K – 333
2021
Q1 		$249K Hold
1,886
– – 0.05% 201
2020
Q4 		$326K Buy
+1,886
New +$258K 0.07% 163

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meristem Family Wealth's NVCR Position: Q2 2021 in Review

Meristem Family Wealth sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 1,886 shares — an estimated $249K sold.

Meristem Family Wealth first reported a position in NVCR in Q4 2020 and held it in 2 quarters. The position peaked at $326K in Q4 2020. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

  • Meristem Family Wealth reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
  • Meristem Family Wealth sold 1,886 NovoCure shares in Q2 2021, an estimated $249K.
  • Meristem Family Wealth first reported a position in NovoCure in Q4 2020 and held it in 2 quarters.
  • Meristem Family Wealth's NovoCure position peaked at $326K in Q4 2020.
  • 361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Meristem Family Wealth's 13F filing for Q2 2021, filed 6 Aug 2021.